Target Name: KIF5C
NCBI ID: G3800
Review Report on KIF5C Target / Biomarker Content of Review Report on KIF5C Target / Biomarker
KIF5C
Other Name(s): Kinesin heavy chain isoform 5C | KINN | Kinesin family member 5C, transcript variant 1 | Kinesin heavy chain neuron-specific 2 | KIF5C_HUMAN | neuron-specific kinesin heavy chain 2 | kinesin family member 5C | kinesin heavy chain neuron-specific 2 | Kinesin, heavy chain, neuron-specific | NKHC2 | KIF5C variant 1 | kinesin-1 | CDCBM2 | KIAA0531 | Kinesin-1 | NKHC | NKHC-2

KIF5C: A Protein Involved in Cellular Processes and Cancer Development

Kinesin Heavy Chain Isoform 5C (KIF5C) is a protein that is expressed in most tissues of the body. It plays a critical role in the intracellular transport of various molecules, including proteins, RNA, and vesicles. KIF5C is composed of four subunits, each of which has a distinct function in the protein. One of the subunits, KIF5A, is the most abundant and well-studied subunit.

KIF5A is a 21-kDa protein that contains 115 amino acid residues. It consists of a catalytic domain, a nucleotide-binding domain, and a carboxy-terminal domain. The catalytic domain is the region of the protein that contains the enzyme's active site, where the substrate binds. The nucleotide-binding domain is the region that interacts with the nucleotides in the substrate. The carboxy-terminal domain is the region that functions as a target for various signaling pathways.

KIF5C functions as a negative regulator of the myosin ATPase, which is a protein that is involved in the production of force during muscle contraction. The myosin ATPase is composed of two subunits, Myosin ATPase (MAAP) and Myosin ATPase regulatory protein (MARP), which are encoded by the genes KOI1 and KOI2, respectively. KIF5C is able to interact with MARP and prevent it from activating the myosin ATPase. This interaction between KIF5C and MARP plays a crucial role in the regulation of muscle contraction and the maintenance of posture.

In addition to its role in regulating myosin ATPase, KIF5C is also involved in the regulation of various other cellular processes. For example, it is a negative regulator of the Par tau protein, which is involved in the regulation of cell growth and differentiation. KIF5C is also a negative regulator of the p21-activated kinase (PAK), which is involved in the regulation of cell proliferation and survival.

KIF5C is a protein that has been identified as a potential drug target and biomarker for various diseases. For example, KIF5C has been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, KIF5C has been linked to the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In conclusion, KIF5C is a protein that plays a critical role in the regulation of various cellular processes and is involved in the development and progression of various types of cancer. As a potential drug target and biomarker, KIF5C is an attractive target for researchers to study and develop new treatments for a variety of diseases.

Protein Name: Kinesin Family Member 5C

Functions: Microtubule-associated force-producing protein that may play a role in organelle transport. Has ATPase activity (By similarity). Involved in synaptic transmission (PubMed:24812067). Mediates dendritic trafficking of mRNAs (By similarity). Required for anterograde axonal transportation of MAPK8IP3/JIP3 which is essential for MAPK8IP3/JIP3 function in axon elongation (By similarity)

The "KIF5C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIF5C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

KIF6 | KIF7 | KIF9 | KIF9-AS1 | KIFAP3 | KIFBP | KIFC1 | KIFC2 | KIFC3 | Killer Cell Immunoglobulin-Like Receptor (KIR) | Killer cell immunoglobulin-like receptor 2DS1, transcript variant X1 | KIN | Kinesin-like protein KIF16B (isoform 1) | KIR2DL1 | KIR2DL2 | KIR2DL3 | KIR2DL4 | KIR2DL5A | KIR2DL5B | KIR2DP1 | KIR2DS1 | KIR2DS2 | KIR2DS3 | KIR2DS4 | KIR2DS5 | KIR3DL1 | KIR3DL2 | KIR3DL3 | KIR3DP1 | KIR3DS1 | KIR3DX1 | KIRREL1 | KIRREL1-IT1 | KIRREL2 | KIRREL3 | KIRREL3-AS2 | KIRREL3-AS3 | KISS1 | KISS1R | KIT | KITLG | KIZ | KIZ-AS1 | KL | KLB | KLC1 | KLC2 | KLC3 | KLC4 | KLF1 | KLF10 | KLF11 | KLF12 | KLF13 | KLF14 | KLF15 | KLF16 | KLF17 | KLF17P1 | KLF2 | KLF3 | KLF3-AS1 | KLF4 | KLF5 | KLF6 | KLF7 | KLF8 | KLF9 | KLHDC1 | KLHDC10 | KLHDC2 | KLHDC3 | KLHDC4 | KLHDC7A | KLHDC7B | KLHDC7B-DT | KLHDC8A | KLHDC8B | KLHDC9 | KLHL1 | KLHL10 | KLHL11 | KLHL12 | KLHL13 | KLHL14 | KLHL15 | KLHL17 | KLHL18 | KLHL2 | KLHL20 | KLHL21 | KLHL22 | KLHL23 | KLHL24 | KLHL25 | KLHL26 | KLHL28 | KLHL29 | KLHL3 | KLHL30